BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 10848699)

  • 1. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
    Hugosson J; Aus G; Becker C; Carlsson S; Eriksson H; Lilja H; Lodding P; Tibblin G
    BJU Int; 2000 Jun; 85(9):1078-84. PubMed ID: 10848699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
    Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
    BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
    Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
    Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
    J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population screening for prostate cancer and emerging concepts for young men.
    Moul JW
    Clin Prostate Cancer; 2003 Sep; 2(2):87-97. PubMed ID: 15040869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
    Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
    Zackrisson B; Aus G; Lilja H; Lodding P; Pihl CG; Hugosson J
    Eur Urol; 2003 Apr; 43(4):327-32. PubMed ID: 12667711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.
    Jyoti SK; Blacke C; Patil P; Amblihalli VP; Nicholson A
    Cancer Causes Control; 2018 Jan; 29(1):87-92. PubMed ID: 28918559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.